[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359120-105":59,"doc-detail-359120-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","treating-pancreatic-ductal-adenocarcinoma-the-targeted-revolution-is-here","Treating Pancreatic Ductal Adenocarcinoma - The Targeted Revolution is Here","","Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal malignancies, driven by an immunosuppressive, hostile tumor microenvironment and KRAS-driven biology that contribute to poor outcomes. Advances in molecular targeting—homologous repair deficiency, KRASG12C mutations, rare gene fusions, and other abnormalities—have improved results for subsets of patients. The review covers emerging targeted agents, claudin-directed biologics, PRMT5 inhibitors, and immunotherapy approaches, summarizing current PDAC therapeutics and key drug development directions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/treating-pancreatic-ductal-adenocarcinoma-the-targeted-revolution-is-here/359120/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/treating-pancreatic-ductal-adenocarcinoma-the-targeted-revolution-is-here/359120.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What factors contribute to poor outcomes in pancreatic ductal adenocarcinoma (PDAC)?","Question",{"text":112,"@type":113},"An immunosuppressive, hostile tumor microenvironment and KRAS-driven tumor biology are major contributors to poor outcomes in PDAC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which molecular targets have recently improved outcomes in subsets of PDAC patients?",{"text":117,"@type":113},"Targeting homologous repair deficiency, KRASG12C mutations, rare gene fusions, and other molecular abnormalities has improved outcomes in selected patient subsets.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is the PDAC tumor immune microenvironment considered a barrier to therapy?",{"text":121,"@type":113},"PDAC shows a dense, fibrotic stroma that limits drug and immune cell penetration by creating physical barriers, elevated interstitial pressure, and hypoxia, alongside immunosuppressive cells that hinder T-cell migration and activation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359120,1790639797,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Drugs (2026) 86:507–532  \n[https://doi.org/10.1007/s40265-026-02295-0](https://doi.org/10.1007/s40265-026-02295-0)  \nTreating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here  \nMichael S. May1,2,3 · Wungki Park1,2,3 · Eileen M. O’Reilly1,2,3  \nReceived: 16 November 2025 / Accepted: 20 January 2026 / Published online: 23 February 2026 © The Author(s) 2026  \nAbstract  \nPancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies and is a rising cause of morbidity and mortality. An immunosuppressive, hostile tumor microenvironment, and KRAS-driven biology have contributed to poor outcomes in PDAC. Recent breakthroughs in targeting tumors with homologous repair deficiency, KRASG12C mutations, rare gene fusions, and other molecular abnormalities have improved outcomes in subsets of patients. KRAS inhibitors, both allele specific and pan(K)RAS, claudin-targeting biologics, and PRMT5 inhibitors have demonstrated single agent activity in pretreated, biomarker selected PDAC. An improved understanding of the tumor immune microenvironment has facilitated the development of promising cancer vaccines and immunomodulating agents. This review summarizes the current state of PDAC therapeutics and describes drug development targets that will transform outcomes in PDAC in the proximate future.  \n* Eileen M. O’Reilly [oreillye@mskcc.org](oreillye@mskcc.org)  \n1 David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA  \n2 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA  \n3 Weill Cornell Medical College, New York, NY, USA  \n1 Background  \nPancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related mortality, following lung and colorectal malignancies. PDAC is arguably the most lethal malignancy with a 5-year survival rate of 8% and incidence rates continue to increase by approximately 1% per year [1] . Despite a revolution in immune-modulatory and targeted therapies, which have transformed outcomes in many cancer types, chemotherapy combinations are the mainstay for most patients with PDAC. However, improvements in molecular characterization and drug development augur the beginning of a more personalized and targeted approach to treatment of PDAC. These advancements have already improved outcomes for patients with germline BRCA1 and BRCA2 variants, mismatch repair deficient tumors, and KRASG12C mutations. Although each of these groups represents a small subset of PDAC, they provide proof of principle that the tumor immune microenvironment (TIME) and PDAC genomic and cellular mechanisms can be successfully targeted.  \nActivating KRAS mutations are the underpinning of PDAC oncogenesis and pathology and are identified in approximately 95% of cases [2] . An additional 3% of cases have alternative mitogen-activated protein kinase (MAPK) pathway alterations, leaving only 2% of cases that are truly MAPKWT [2] . These mutations transform a fundamental regulator of cell survival and  \ndivision, into a constitutively “on” pathway facilitating unregulated tumor cell growth and invasion. Decades of approaches of targeting KRAS directly and indirectly have been unsuccessful, and targeting of other MAPK pathway targets has not shown promise in PDAC outside of BRAFV600E mutant disease [3] . However, KRASG12C inhibitors have recently shown efficacy and gained approval in non-small cell lung cancer (NSCLC) [4 , 5], colorectal cancer [6], and guideline endorsement in PDAC [7] . KRASG12C mutations are present in about 1% of PDAC, but KRASG12C inhibitors have paved the way for the ongoing development of numerous targeted therapies against specific mutant alleles of KRAS (particularly KRASG12D) and activated KRAS.  \nIn KRAS mutant PDAC, the most common comutations of driver oncogenes include TP53 (78%), CDKN2A/B (39%), and SMAD4 (24%), which have to date not represented promising targets for drug development [2] . Ho","cbCaipaTHPrG60rq","https://ap.wps.com/l/cbCaipaTHPrG60rq","pdf",1329936,26,"English","# Background\n## Epidemiology and current treatment landscape\n## KRAS and molecular subtypes\n## Tumor immune microenvironment\n# Standard of Care Therapies\n## Best available chemotherapy regimens for mPDAC","[{\"question\":\"What factors contribute to poor outcomes in pancreatic ductal adenocarcinoma (PDAC)?\",\"answer\":\"An immunosuppressive, hostile tumor microenvironment and KRAS-driven tumor biology are major contributors to poor outcomes in PDAC.\"},{\"question\":\"Which molecular targets have recently improved outcomes in subsets of PDAC patients?\",\"answer\":\"Targeting homologous repair deficiency, KRASG12C mutations, rare gene fusions, and other molecular abnormalities has improved outcomes in selected patient subsets.\"},{\"question\":\"Why is the PDAC tumor immune microenvironment considered a barrier to therapy?\",\"answer\":\"PDAC shows a dense, fibrotic stroma that limits drug and immune cell penetration by creating physical barriers, elevated interstitial pressure, and hypoxia, alongside immunosuppressive cells that hinder T-cell migration and activation.\"}]","Treating Pancreatic Ductal Adenocarcinoma - The Targeted Revolution is Here | PDF",1790136158,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8db0b52d25700333c8e12fe9c7a5edd6.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe6a9a625c0aedee9c4fe544508f16c3.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1c24c4711975aae250c9bc2362e0362.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0bbe1bdf7e8655a67fc4e40876083766.webp",980,1301]